stoxline Quote Chart Rank Option Currency Glossary
Global Blood Therapeutics, Inc. (GBT)
68.49  0.01 (0.01%)    10-04 16:00
Open: 68.48
High: 68.49
Volume: 3,279,961
Pre. Close: 68.48
Low: 68.47
Market Cap: 0(M)
Technical analysis
2022-11-18 4:20:54 PM
Short term     
Mid term     
Targets 6-month :  79.99 1-year :  93.43
Resists First :  68.48 Second :  79.99
Pivot price 68.48
Supports First :  68.47 Second :  68.47
MAs MA(5) :  68.48 MA(20) :  68.48
MA(100) :  59.24 MA(250) :  41.38
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  100 D(3) :  100
RSI RSI(14): 77.1
52-week High :  73.01 Low :  21.64
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GBT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 68.65 - 68.99 68.99 - 69.26
Low: 67.51 - 67.98 67.98 - 68.37
Close: 67.84 - 68.54 68.54 - 69.12
Company Description

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Headline News

Tue, 01 Aug 2023
Syros seeking new partner for its SCD program after Pfizer ends... - Sickle Cell Disease News

Fri, 21 Jul 2023
Pfizer to end license deal with Syros for blood disorder therapies -

Tue, 11 Jul 2023
Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ ... - PR Newswire

Wed, 07 Jun 2023
Ted Love, now the chair of biotech's big trade group, talks drug ... - The Business Journals

Wed, 05 Oct 2022
Pfizer Completes Acquisition of Global Blood Therapeutics - Pfizer

Tue, 23 Aug 2022
Pfizer Bidding War With J&J Preceded Global Blood Therapeutics ... - Bloomberg

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 64 (M)
Shares Float 53 (M)
Held by Insiders 2.7 (%)
Held by Institutions 116.1 (%)
Shares Short 9,230 (K)
Shares Short P.Month 10,650 (K)
Stock Financials
EPS -4.04
EPS Est Next Qtrly -0.68
EPS Est This Year -2.45
EPS Est Next Year -2.92
Book Value (p.s.) 6.71
Profit Margin -146.9 %
Operating Margin -137.4 %
Return on Assets (ttm) -23.9 %
Return on Equity (ttm) -124.6 %
Qtrly Rev. Growth 41.2 %
Gross Profit (p.s.) 2.97
Sales Per Share 3.27
EBITDA (p.s.) -4.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -249 (M)
Levered Free Cash Flow -136 (M)
Stock Valuations
PE Ratio -16.96
PEG Ratio -0.2
Price to Book value 10.19
Price to Sales 20.93
Price to Cash Flow -17.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android